Back to News
Market Impact: 0.25
CMS Maintains Favorable SCINTIX Therapy Reimbursement for 2027
Source: Business Wire
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
CMS maintained premium reimbursement for RefleXion's X2 platform for the third consecutive year. The company said the reimbursement adds to the platform's economic value; no reimbursement amount or market reaction was provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Tech stock rout, driven by US AI fears, continues in Asian trading
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- Paraguay’s Santiago Pena under arrest, new president Pedro Alliana sworn in